ScreenerHero

TECXTectonic Therapeutic Inc. Common Stock

NAS · US · Healthcare · Biotechnology · tectonictx.com
37.63USD+1.59%Mkt Cap: 735.64M $P/E: —

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe tech…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap735.64M $
Enterprise Value482.09M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-74.15M $
Revenue/Share—
Last Price37.63 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees60
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.70
PEG—
EV/EBITDA-5.15
EV/Revenue—
P/S—
P/B2.95
EPS (TTM)-4.44
EPS (Forward)-4.68
52W Range
14.3992% of range39.53
52W High39.53 USD
52W Low14.39 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-29.50%
ROA-28.41%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-60.08M $
CapEx (TTM)208.00K $
FCF Margin—
FCF Yield-6.35%
Net Debt-222.67M $
Net Debt/EBITDA2.38
Balance Sheet
Debt/Equity0.01
Current Ratio22.29
Quick Ratio21.90
Book Value/Sh12.24 USD
Cash/Share11.62 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJun 21, 2024
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)77.56 USD
Upside (mean)+106.1%
Target Range60.00 USD – 93.00 USD
$60.00+106.1% to mean$93.00
# Analysts9
Ownership
Shares Out.19.55M
Float11.91M
Insiders37.85%
Institutions71.69%
Short Interest
Short Ratio8.5d
Short % Float18.26%
Short % Out.9.03%
Shares Short1.76M
Short (prev mo.)2.14M
Technical
SMA 5032.15 (+17.1%)
SMA 20026.50 (+42.0%)
Beta0.22
S&P 52W Chg18.16%
Avg Vol (30d)176.13K
Avg Vol (10d)259.52K
Technical Indicators
RSI (14)64.2
MACD1.2756
MACD Signal0.5015
MACD Hist.+0.7741
BB Upper37.86 USD
BB Middle31.70 USD
BB Lower25.54 USD
BB Width38.84%
ATR (14)2.161 USD
Vol Ratio (20d)1.10x